Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1

Conditions

Urinary Bladder Neoplasms 1Oligoprogressive 1Lymphatic Metastasis 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Sunitinib 27Nivolumab 26pembrolizumab 23Sorafenib 17Everolimus 14Cyclophosphamide 13Interleukin-2 10Bevacizumab 10Radiosurgery 9spartalizumab 8pazopanib 7atezolizumab 7Ipilimumab 7Axitinib 7fludarabine 6aldesleukin 6cabozantinib 5Radiotherapy 5Magnetic Resonance Spectroscopy 5Immunohistochemistry 5Gemcitabine 5peginterferon alfa-2b 4avelumab 4Nephrectomy 4Irinotecan 4Introns 4Gene Expression Profiling 4Capecitabine 4lenvatinib 3fludarabine phosphate 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Carcinoma, Renal Cell × DEAE-Dextran × Clear all
NCT05846646 2025-10-20

Study of PULSAR-ICI +/- IMSA101 in Patients With Oligometastatic NSCLC and RCC

ImmuneSensor Therapeutics Inc.

Phase 2 Terminated
6 enrolled 7 charts
GenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡